Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 29;223(11):1855–1864. doi: 10.1093/infdis/jiaa016

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 3. — Relationships between linezolid (LZD) pharmacokinetic/pharmacodynamics parameters and change in lung colony-forming unit (CFU) counts in each infection model. (A) Linezolid monotherapy in acute infection model. (B) Linezolid in combination with pretomanid at 12.5 mg/kg in acute infection model. (C) Linezolid monotherapy in chronic infection model. (D) Linezolid in combination with pretomanid at 50 mg/kg in acute infection model. Dotted horizontal line indicates no change from CFU count in untreated controls (A and C) or no change from CFU count after treatment with pretomanid alone (B and D). AUC/MIC, area under the concentration-time curve above the minimum inhibitory concentration; C_max, LZD maximum concentration; Time_>MIC, time above minimum inhibitory concentration.